HIV and Headache: A Cross‐Sectional Study

Rocha-Filho, Pedro Augusto Sampaio; Torres, Rinailda Cascia Santos; Montarroyos, Ulísses Ramos

doi:10.1111/head.13183

Cited by 18 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Headache was associated with impaired functional status and significant headacheassociated disability in this cohort, similar to other studies in Africa (Woldeamanuel, Andreou et al 2014, Morgan, Eguia et al 2015, Zebenigus, Tekle-Haimanot et al 2017 and in HIV+ cohorts (Kirkland, Kirkland et al 2012, Sampaio Rocha-Filho, Torres et al 2017. A study in Zambia reported headaches led to lost working days which they estimated accounted for a loss in the national gross domestic product of nearly 2% .…”

Section: Discussionsupporting

confidence: 82%

Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda

et al. 2019

View full text Add to dashboard Cite

Headache is common, but its prevalence and impact in sub-Saharan Africa and especially in HIV+ individuals is relatively unknown. We sought to determine the prevalence and functional impact of headache among HIV-infected (HIV+) adults in a cross-sectional observational cohort study in rural Rakai District, Uganda. Participants completed a sociodemographic survey, depression screen, functional status assessments, and answered the headache screening question, "Do you get headaches?" Participants responding affirmatively were assessed with the ID Migraine tool for diagnosis of migraine and Headache Impact Test-6 to determine functional impact of headache. Characteristics of participants with and without headaches and with and without functional impairment were compared using t-tests for continuous variables, chi-square tests for categorical variables, and multivariate logistic regression. Of 333 participants, 51% were males, mean age was 37 (SD 9) years, 94% were on antiretroviral therapy (ART) and mean CD4 count was 403 (SD 198) cells/µL. Headache prevalence was 28%. Among those reporting headache, 19% met criteria for migraine, 55% reported functional impairment, and 37% reported substantial or severe impact

show abstract

Section: Discussionsupporting

confidence: 82%

Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Migraine-like headaches have already been described in association with viral infections (22–26). For our patients who experienced previous migraines, the headache they experienced associated with COVID-19 was most often of a migraine phenotype.…”

Section: Discussionmentioning

confidence: 99%

Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia

2020

Self Cite

View full text Add to dashboard Cite

Objectives To assess the frequency and characteristics of headache in patients with COVID-19 and whether there is an association between headache and anosmia and ageusia. Methods This was a cross-sectional study. Consecutive patients admitted to hospital with COVID-19, confirmed by reverse transcription polymerase chain reaction (RT-PCR) technique, were assessed by neurologists. Results Seventy-three patients were included in the study, 63% were male; the median age was 58 years (IQR: 47–66). Forty-seven patients (64.4%) reported headaches, which had most frequently begun on the first day of symptoms, were bilateral (94%), presenting severe intensity (53%) and a migraine phenotype (51%). Twelve patients (16.4%) presented with headache triggered by coughing. Eleven (15%) patients reported a continuous headache. Twenty-eight patients (38.4%) presented with anosmia and 29 (39.7%) with ageusia. Patients who reported hyposmia/anosmia and/or hypogeusia/ageusia experienced headache more frequently than those without these symptoms (OR: 5.39; 95% CI:1.66–17.45; logistic regression). Patients with anosmia and ageusia presented headache associated with phonophobia more often compared to those with headache without these complaints (Chi-square test; p < 0.05). Headache associated with COVID-19 presented a migraine phenotype more frequently in those experiencing previous migraine ( p < 0.05). Conclusion Headaches associated with COVID-19 are frequent, are generally severe, diffuse, present a migraine phenotype and are associated with anosmia and ageusia.

show abstract

“…Stress during COVID-19 could be a trigger of migraine attacks and may have a role in this worsening. In the other hand worsening of primary headaches could be explained by viral diseases [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study

et al. 2021

View full text Add to dashboard Cite

Background Coronavirus disease-19 is caused by the severe acute respiratory syndrome coronavirus 2 Headache is a common symptom during and after Coronavirus disease-19. We aimed to study headache character in relation to COVID-19. Methods This was a cross-sectional study. Patients who had Coronavirus disease-19, confirmed by reverse transcription polymerase chain reaction technique and presented to the headache clinic within 3 months after the onset of infections were identified to the study. Study included patients diagnosed as primary headache disorders according to The International Classification of Headache Disorders, 3rd edition. Participants were grouped into categories according to having previous or de novo headache. Descriptive data, paired sample t-test and the chi-squared test (X2) were used for statistical analyses of the data. Results A total of 121 patients were included in this study. Their mean age was 35.29 + 9.54 and most of them were females (83.5%). Prior to Coronavirus disease-19 infections, 78 (64.5%) had migraine and 11(9.1%) experienced a tension-type headache while 32 (26.4) reported de novo headache post Coronavirus disease-19. Patient had significant increase in headache days 11.09 ± 8.45 post Coronavirus disease-19 compared with 8.66 ± 7.49 headache days before Coronavirus disease-19 infection (p < 0.006). Post Coronavirus disease-19, the usage of analgesic increased significantly by the patient with migraine (2.31 ± 1.65 vs 3.05 ± 2.09, p = 0.002) while the patient with tension type headache had statistically significant increase in severity (5.556 ± 1.86 vs 7 ± 2.25, p = 0.033) and frequency (7 ± 6.29 vs 12.72 ± 7.96, p = 0.006) of headache attacks. Bi-frontal and temporal headache are the most reported (40.6% each) headache site among de novo headache group. Patients younger than 40 years had longer duration of the headache attack (18.50 ± 16.44 vs 5.5 ± 9.07, p = 0.045) post COVID-19. Male patients compared to females (8.66 ± 1.15 versus 5.93 ± 2.01 p = 0.04) had more severe headache post Coronavirus disease-19. De novo headache resolved within 1 month in most of patients (65.3%). Conclusion Primary headache get worse after Coronavirus disease-19. De novo primary headache is frequent post Coronavirus disease-19 and resolve within 1 month. Headaches related to Coronavirus disease-19 are severe, present as migraine phenotype. Young male patients with Coronavirus disease-19 tend to have worse headache.

show abstract

HIV and Headache: A Cross‐Sectional Study

Abstract: HIV-positive patients had a high frequency of headaches, which had a great impact on patients' lives. The pattern most often found was migraine. There was no correlation between CD4 counts and the severity of headaches.

Cited by 18 publications

References 21 publications

Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda

Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda

Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia

Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study

Contact Info

Product

Resources

About